Dividend compounder review

LGND

Ligand Pharmaceuticals Incorporated · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score68.05/100
Confidence100.00/100
DecisionWatchlist
RatingAcceptable, Needs Review
Scoring

Quality breakdown

Dividend Reliability 2.5 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 20.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 23.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 10.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 12.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years1
Dividend Yield3.66%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$124.5M
Free Cash Flow$38.0M
FCF Covers DividendYes
Debt / Equity0.45
P/E33.4
Revenue Growth 5Y10.4%
Net Margin55.9%
ROE17.1%
Price vs Trend23.6%
3Y Return249.6%
5Y Return193.9%
CurrencyUSD
Warnings

Review flags

Dividend history is short: 1 completed years.
Dividend diary

Activity record

LGND dividend review warning Warning · Warning

Dividend history is short: 1 completed years.

LGND qualified as a dividend compounder candidate Qualified · Positive

Score 68.05/100, decision Watchlist.

LGND dividend payment 9.357 USD Dividend Payment · Info

Recorded dividend payment for Ligand Pharmaceuticals Incorporated.